Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading on Wednesday. Investors purchased 1,002 put options on the stock. This is an increase of 1,791% compared to the average volume of 53 put options.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Stifel Nicolaus reduced their target price on Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, February 23rd. Craig Hallum assumed coverage on Maravai LifeSciences in a research report on Wednesday, April 10th. They set a “buy” rating and a $15.00 target price on the stock. Finally, Royal Bank of Canada upped their target price on Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Maravai LifeSciences has an average rating of “Moderate Buy” and a consensus target price of $11.56.

Institutional Trading of Maravai LifeSciences

Hedge funds have recently modified their holdings of the stock. Zions Bancorporation N.A. purchased a new position in Maravai LifeSciences during the first quarter worth approximately $28,000. Gladius Capital Management LP acquired a new position in shares of Maravai LifeSciences during the fourth quarter valued at approximately $30,000. Meeder Asset Management Inc. acquired a new position in shares of Maravai LifeSciences during the first quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Maravai LifeSciences by 96.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company’s stock valued at $34,000 after acquiring an additional 1,662 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Maravai LifeSciences by 99.9% during the third quarter. Signaturefd LLC now owns 3,364 shares of the company’s stock valued at $34,000 after acquiring an additional 1,681 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Down 1.6 %

Shares of MRVI opened at $7.61 on Friday. Maravai LifeSciences has a 52 week low of $4.52 and a 52 week high of $16.62. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -8.46 and a beta of 0.01. The stock’s 50-day moving average price is $7.52 and its 200-day moving average price is $6.77.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. The company had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $62.99 million. On average, sell-side analysts predict that Maravai LifeSciences will post -0.15 EPS for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.